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Background. Studies of hypothalamic–pituitary–adrenal (HPA) axis function in chronic fatigue syndrome (CFS)
point to hypofunction, although there are negative reports. Suggested mechanisms include a reduced hypothalamic or
supra-hypothalamic stimulus to the HPA axis and enhanced sensitivity to the negative feedback of glucocorticoids. The
aim of the current study was to investigate HPA axis function in CFS with the dexamethasone/corticotropin-releasing
factor (Dex/CRF) test, in analogy with research in aﬀective disorders.
Method. Thirty-four well-characterized female CFS patients and 25 healthy control subjects participated in the
low-dose Dex/CRF test. Current major depressive episode was an exclusion criterion. History of early-life stress (ELS)
was assessed with the Structured Trauma Interview.
Results. Salivary cortisol responses after 0.5 mg Dex were lower in CFS patients than in controls (before 100 mg CRF,
p=0.038 ; after 100 mg CRF, p=0.015). A secondary analysis revealed an inﬂuence of early-life stress and of oestrogen
intake. After removal of the 10 participants who were taking an oral oestrogen, patients without a history of ELS showed
lower cortisol responses than patients with ELS and controls (before CRF, p=0.005 ; after CRF, p=0.008).
Conclusions. CFS is globally associated with reduced cortisol responses in the combined low-dose Dex/CRF test,
but this eﬀect is only clearly present in CFS patients without a history of ELS. This study provides further support
for an enhanced glucocorticoid negative feedback and/or a reduced central HPA axis drive in CFS. Furthermore, it
demonstrates that ELS is an important variable to consider in CFS research.
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Introduction
Chronic fatigue syndrome (CFS) is characterized by
unexplained, profound disabling and long-lasting
fatigue that is of new or deﬁnite onset, that is not the
result of ongoing exertion and that is not substantially
alleviated by rest. The fatigue must be accompanied
by at least 4 or more of the following case-deﬁning
symptoms during at least 6 months of consecutive
illness : sore throat, tender cervical or axillary lymph
nodes, muscle pain, multi-joint pain, post-exertional
malaise, unrefreshing sleep, headaches and impaired
memory or concentration (Fukuda et al. 1994). The
suggestion that CFS may be related to a dysfunction
of the hypothalamic–pituitary–adrenal (HPA) axis
derives from the similarity in symptoms between CFS
patients and patients with Addison’s disease or after
bilateral adrenalectomy (Cleare, 2003). Moreover, the
HPA axis oﬀers an interesting physiological basis for
the link between CFS, immunological disturbances
and physical or psychological stress (Gold &
Chrousos, 2002 ; Gerrity et al. 2004 ; Van Houdenhove
& Egle, 2004). In the past, stress has generally been
associated with HPA axis hyperactivity, resulting
in hypercortisolism. However, chronic stress can also
lead to hypocortisolism, as is the case in several stress-
related disorders (Heim et al. 2000a ; Gold & Chrousos,
2002 ; Fries et al. 2005). In CFS, the overall balance of
evidence points to reduced cortisol output in at least
a proportion of the patients, despite the negative
reports and the poor quality of many studies (Cleare,
2003).
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In addition to measurements of basal hormone
concentrations, dynamic challenges of the HPA axis
have been undertaken for several reasons : to inves-
tigate at which level there may be abnormalities in
the control of the HPA axis, to detect more subtle
disturbances of the axis and to provide a more reliable
and standardized indicator of the HPA axis disturb-
ance (Cleare, 2003). Blunted responses of cortisol and/
or adrenocorticotropic hormone (ACTH) to awaken-
ing and to several challenge tests [corticotropin-
releasing factor (CRF), insulin tolerance test, naloxone,
social stress and exercise] have been reported in CFS
(Demitrack et al. 1991 ; Scott et al. 1998a, b ; Gaab
et al. 2002a ; Roberts et al. 2004). Suggested mech-
anisms for the ﬁndings in these challenge studies
in CFS include a deﬁciency of hypothalamic CRF or
vasopressin and a reduced supra-hypothalamic
stimulus to the HPA axis, resulting in hypocortisolism
(Demitrack et al. 1991 ; Demitrack & Croﬀord, 1998 ;
Scott et al. 1998a, 1999 ; Gaab et al. 2002a). Another
possible mechanism of hypocortisolism is enhanced
sensitivity to the negative feedback of glucocorticoids,
also referred to as dexamethasone (Dex) hypersup-
pression (Heim et al. 2000a ; Fries et al. 2005). As to
this mechanism, Gaab et al. (2002b) have demon-
strated that patients with CFS show an enhanced
and prolonged suppression of salivary free cortisol
after the administration of a low dose of Dex
(0.5 mg). Further support for enhanced sensitivity
for glucocortocoids in CFS comes from in vitro
studies, showing that lower concentrations of Dex
were needed to inhibit interleukin production and
proliferation of peripheral blood mononuclear cells
from subjects with CFS (Visser et al. 1998, 2001a, b ;
Gaab et al. 2003a).
Surprisingly, there are no published reports on
investigations with the combined Dex/CRF test in
CFS. This is in contrast with research in major
depressive disorder (MDD), a syndrome that is –
inversely to CFS – characterized by hyperfunction of
the HPA axis, reduced glucocorticoid negative feed-
back (Dex hyposuppression) and hypercortisolism
(Plotsky et al. 1998 ; Claes, 2004). More precisely, the
combined (high-dose) Dex/CRF test has been shown
to be the most sensitive HPA axis function test in
MDD (Heuser et al. 1994a). In this test, the CRF-
induced ACTH and cortisol secretion is signiﬁcantly
higher in most depressed patients in comparison to
healthy controls if a high-dose Dex (1.5 mg) pre-
treatment is administered in the evening preceding the
CRF challenge (Heuser et al. 1994a). Both reduced
glucocorticoid negative feedback and increased cen-
tral drive of the HPA axis have been proposed as
underlying mechanisms in MDD (Cole et al. 2000 ;
Holsboer, 2000).
The aim of this study was to compare the cortisol
responses in the low-dose (0.5 mg) combined Dex/
CRF test between well-characterized patients with
CFS and healthy controls without CFS. It was expected
that CFS would be associated with a reduced
cortisol response in this test, due to enhanced negative
feedback and/or reduced central drive of the HPA
axis.
Method
Subjects
Patients attending the CFS clinic of the Department
of Internal Medicine of Antwerp University Hospital
were invited to participate in the study by letter. As
described in the literature (Jason et al. 1999), the ma-
jority of the patients were women. Since gender is an
important variable in HPA axis research (Heuser et al.
1994b ; Kirschbaum et al. 1999 ; Ku¨nzel et al. 2003) and
since only a few men responded to the invitation, only
female patients were included. CFS was diagnosed
according to the Center for Disease Control Criteria
(Fukuda et al. 1994) by an experienced internist (G.M.).
All patients underwent serial physical examinations
and laboratory evaluations ; no alternative medical
diagnosis could be established. Initially, 35 patients
were included. One patient was excluded due to a
panic attack during the Dex/CRF test, leaving 34
patients. Twenty-ﬁve healthy females without a
past history of CFS were recruited by an advertise-
ment in Antwerp University Hospital. They were
matched for age and educational level. Five levels of
education were considered in accordance with the
Belgian education system. The patient group was
larger in order to allow a secondary analysis of
potential inﬂuencing clinical variables within this
group. The data were collected between October 2003
and November 2004. Pregnancy, a lifetime history of
organic brain disease, current medical condition or
drugs that might inﬂuence neuroendocrine testing
(with the exception of psychotropic drugs and oral
contraceptives) were exclusion criteria. All partici-
pants were Caucasian and had grandparents of
European origin. The Medical Ethical Committee of
the University Hospital of Antwerp approved the
study. All participants were aged >18 years and
signed informed consent.
Interviews and questionnaires
All participants were interviewed with the Dutch
version of SCID-I/P version 2.0 (First et al. 1999) by
a trained psychiatrist (F.V.D.E.). The CDC psychiatric
exclusion criteria for CFS were adopted, with three
exceptions. First, subjects who met the criteria for
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a current major depressive episode according to
DSM-IV (APA, 1994) were excluded, in order to avoid
a state eﬀect of MDD on the outcome in the Dex/CRF
test. Second, a history of melancholic depression was
not assessed systematically, because the speciﬁcation
of melancholic features in the past is not provided in
SCID-I/P and because it is diﬃcult to assess this item
retrospectively by means of an interview. Finally, one
control subject had suﬀered from anorexia nervosa in
the past, but was in complete remission for more than
5 years. The Checklist Individual Strength was used to
measure patient’s perceived fatigue concentration,
motivation and physical activity. This 20-item self-
rating scale is well validated and reliable (Vercoulen
et al. 1999).
One of the factors potentially determining hetero-
geneity and inﬂuencing the HPA axis in CFS is early-
life stress (ELS), consisting of sexual, physical and/or
emotional maltreatment during childhood (Van Den
Eede et al. 2007). Preclinical animal laboratory studies
have provided evidence that ELS (maternal separation
in rats or adverse rearing conditions in non-human
primates) produces long-lived hyperactivity of CRF
neuronal systems, as well as greater reactivity of the
HPA axis (Plotsky & Meaney, 1993 ; Coplan et al. 1996 ;
Ladd et al. 1996 ; Heim et al. 2004). In accordance with
these ﬁndings, higher pituitary reactivity to CRF and
to psychological stress has been described in adult
women with a history of childhood abuse (Heim et al.
2000b, 2001). In addition, Rinne et al. (2002) demon-
strated that ELS was associated with an enhanced
ACTH and cortisol response in the high-dose Dex/
CRF test in women with borderline personality dis-
order, pointing to an enhanced central CRF drive and
a reduced glucocorticoid negative feedback. This is in
contrast with the proposed central CRF deﬁciency and
enhanced glucocorticoid negative feedback in CFS. As
a consequence, it may be that CFS patients with a
history of ELS constitute a subgroup with a diﬀerent
neuroendocrine function (Van Den Eede et al. 2007).
For the assessment of ELS, the Dutch version of the
Structured Trauma Interview was used (Draijer, 1989).
This instrument is described in detail elsewhere
(Draijer & Langeland, 1999). There have been reports
of signiﬁcant associations between childhood abuse
scores in the Structured Trauma Interview and both
responses to a challenge of the serotonin system
(Rinne et al. 2000) and to cortisol responses in the
Dex/CRF test (Rinne et al. 2002). All interviews were
conducted by a psychiatrist (F.V.D.E.) at the end of
the clinical and psychiatric investigation in a context
of absolute conﬁdentiality and mutual trust. The focus
of the Structured Trauma Interview is on childhood
sexual and physical abuse. Physical abuse is deﬁned
as intentional physical aggression by a parent or
caregiver towards a child (<16 years), which may
cause injuries. Physical aggression was coded as
‘severe’ if it happened more than once a month and if
it sometimes led to injuries. When individuals were hit
hard more than once a month without experiencing
injuries, or when aggression took place less frequently
but with injuries, it was scored as ‘moderate’. ‘Mild’
aggression had a lower frequency and was not
accompanied with injuries. Sexual abuse is deﬁned
as sexual contacts with a child (<16 years), which
took place against her/his will or when she/he had
the feeling that the sexual contacts could not be re-
fused due to physical or relational preponderance,
emotional pressure, force or violence. This item was
coded as severe when it appeared chronically or more
than once a month during a period in childhood, when
it consisted of any form of penetration, when it was
associated with violence or when it appeared in the
primary support group. ELS was deﬁned as moderate
or severe physical abuse and/or severe sexual abuse.
Combined low-dose Dex/CRF test
The combined low-dose Dex/CRF test was performed
at Antwerp University Hospital following the
protocol described by Heuser et al. (1994a). However,
instead of measuring plasma cortisol, we measured
salivary cortisol concentration by means of a cotton-
wool Salivette (Sarstedt, Nu¨mbrecht, Germany). Sali-
vary cortisol is considered as an easy-to-asses correlate
of the unbound free hormone fraction (Kirschbaum &
Hellhammer, 1994 ; Baghai et al. 2002). Participants
took 0.5 mg Dex orally at 23:00 hours on the evening
before neuroendocrine testing. At 13:30 hours they
attended the research unit where an infusion (NaCl
0.9%) was placed in the forearm. Participants then
fastened, remained semi-supine or supine under rest-
ing conditions, and were not allowed to sleep. Human
CRF (100 mg) was administered and ﬂushed through
the infusion at 15:00 hours Free salivary concentration
was assessed at seven time-points (14:00, 14:30, 15:00,
15:30, 15:45, 16:00 and 16:15 hours). All saliva samples
were stored at x20 xC and were later delivered to
the Laboratory of Physiology of Reproduction of
the University of Lie`ge. A radioimmunoassay was
performed on 100 ml of salivary free cortisol samples
in competition, with a HPLC preparation of cortisol-
3CMO coupled with 2-[125I]iodohistamine as tracer,
for speciﬁc antibodies raised against cortisol-3CMO-
BSA. The incubation conditions were at 4 xC over-
night. The lower detection limit of the assay was
0.1 nmol/l, the intra-assay coeﬃcient of variation
(CV) was 4.30% (n=10) whereas the inter-assay CV
for low and high cortisol levels were 12.26% and
9.38% (n=30) respectively.
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Statistical analysis
The following three measures were computed: Basal,
AUCtot and AUCnet. Basal represents the mean free
cortisol concentration (in ng/100 ml) over the three
time-points on the day after Dex administration (Dex
suppression), and before the infusion of CRF. The
area under the curve (AUC) was calculated to incor-
porate the cortisol concentrations at the four time-
points after CRF, according to the trapezoid method
(Pruessner et al. 2003). AUCtot is the total area under
the curve and represents the total cortisol output.
AUCnet is identical to AUCtot, except for the removal
of the area between the ground and Basal. This
measure reﬂects the absolute increase of cortisol
after CRF. For statistical analysis, we used SPSS for
Windows, version 12.0 (SPSS Inc., Chicago, IL, USA).
The Kolmogorov–Smirnov test was adopted to exam-
ine the distribution of the data. In view of deviations
from normal distribution and the relatively small
sample size of the subgroups, neuroendocrine vari-
ables were assessed non-parametrically. The Mann–
Whitney test was used for two independent samples
and the Kruskal–Wallis test was used for three
independent samples, followed by the Dunn test for
post-hoc analysis. One-sided testing was applied when
comparing patients and controls, since it was expected
that CFS would be associated with an enhanced sup-
pression of the HPA axis (Gaab et al. 2002b) and thus
a lower cortisol response in the low-dose combined
Dex/CRF test. The following clinical variables were
noted in the patient group: ELS, past history of MDD,
use of benzodiazepines, use of antidepressants and
use of oral oestrogens (two-sided testing). For the
analysis of the sample characteristics, x2 analysis was
applied to compare frequencies. Fisher’s exact test
was used when necessary. If quantitative data failed to
satisfy the assumptions for parametrical statistical
analyses, they were analysed non-parametrically. For
all analyses, a p value<0.05 was adopted as the level
of signiﬁcance.
Results
Characteristics of study groups
Characteristics of the study groups are presented
in Table 1. All patients (with one exception) were
unable to work because of chronic fatigue, whereas all
control subjects had a working employment status.
As expected, the scores on the diﬀerent items of
the Checklist Individual Strength were signiﬁcantly
higher in the patient group (Vercoulen et al. 1999).
None of the participants met the criteria for a current
diagnosis of post-traumatic stress disorder (PTSD),
although this was not an exclusion criterion. As
expected, there was a higher frequency of other cur-
rent anxiety disorders [speciﬁc phobia (n=1), social
phobia (n=1), generalized anxiety disorder (n=3),
panic disorder with or without agoraphobia (n=3),
anxiety not otherwise speciﬁed (n=1)] and a higher
frequency of a history of one or more major depressive
episodes in the patient group (Afari & Buchwald,
2003). None of the controls were diagnosed with
generalized anxiety disorder or panic disorder and
none of the participants had obsessive–compulsive
disorder. The severity of the current anxiety disorders
in both samples was mild or moderate ; in three parti-
cipants the anxiety disorder was in partial remission.
The frequency of ELS was not diﬀerent between the
patients and the controls.
In relation to medication, there were diﬀerences in
the frequency of individuals who were taking oral
oestrogens (all but one as oral contraceptive), anti-
depressants and benzodiazepines. Patients took the
following antidepressants : amitriptyline (n=3,
25–75 mg/day) ; paroxetine (n=3, 20–30 mg/day) ;
citalopram (n=2, 20 mg/day) ; escitalopram (n=1,
10 mg/day) ; ﬂuoxetine (n=1, 20 mg/day) ; mirtaz-
apine (n=1, 30 mg/day) ; melitracen/ﬂupentixol
(n=1, 10/0.5 mg/day) and trazodone (n=1, 50 mg/
day). In addition, four patients were treated with
trazodone as a second antidepressant for sleep dis-
turbances (50–150 mg/day). Furthermore, 10 patients
took f1 mg/day clonazepam and one patient took
2 mg/day. The other benzodiazepines were: tetra-
zepam (n=3), lorazepam (n=2), lormetazepam
(n=2), alprazolam (n=2) and prazepam (n=1) in
patients, and lormetazepam (n=1) and tetrazepam
(n=1) in controls.
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Fig. 1 presents the mean free salivary cortisol re-
sponses in CFS patients and controls in the combined
Dex/CRF test. The mean cortisol responses before
and after CRF were lower in the patient sample.
Table 2 lists the mean vales of the three Dex/CRF
variables (Basal, AUCtot and AUCnet) with the stan-
dard deviations. None of these variables showed a
normal distribution in either sample (Kolmogorov–
Smirnov, p<0.020). In the non-parametrical testing
(Mann–Whitney, one-sided), patients showed signiﬁ-
cantly lower values of Basal and AUCtot and a trend
towards lower values of AUCnet.
When comparing CFS patients with (n=12) and
without ELS (n=22) (ELS+/ELSx), the cortisol re-
sponses before and after CRF were signiﬁcantly lower
in the ELSx group (Mann–Whitney, two-sided: Basal,
p=0.016 ; AUCtot, p=0.008; AUCnet, p=0.012). Re-
garding the patient characteristics, there was a higher
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frequency of patients who experienced one or more
major depressive episodes in the past in the patient
group with ELS (75%) compared to patients without
ELS (37%) (p=0.038), which is consistent with ﬁnd-
ings in other studies (Chapman et al. 2004). With the
exception of a higher level of subjective complaints
of concentration (as measured with Checklist Indi-
vidual Strength) in the ELS+ group, there were
no other signiﬁcant diﬀerences in characteristics be-
tween both patient groups. Within the control group,
subjects with ELS (n=10) showed lower cortisol re-
sponses before and after CRF than subjects without
ELS (n=15), inversely to the ﬁndings in the patient
group. However, the diﬀerences between the two
groups were not statistically signiﬁcant (Mann–
Whitney, two-sided: Basal, p=0.375; AUCtot, p=
0.405 ; AUCnet, p=1).
There were no signiﬁcant diﬀerences in the dis-
tributions of any of the three Dex/CRF variables
between patients with and without a history of one
or more major depressive episodes in the combined
Dex/CRF test (p>0.45). ELS and MDD were cor-
related, but within the CFS group with a history of
one or more major depressive episodes (n=16),
cortisol responses remained signiﬁcantly diﬀerent
between ELSx (n=7) and the ELS+ (n=9) patients
(Mann–Whitney, two-sided: Basal, p=0.017 ; AUCtot,
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Fig. 1.Mean salivary (free) cortisol values (ng/100 ml)¡S.E.M.
at seven time-points during the combined low-dose
dexamethasone/corticotropin-releasing factor (CRF) test in
CFS patients (&, n=34) and in control subjects (m, n=25).
Participants took 0.5 mg dexamethsone orally at 23:00 hours
on the evening before neuroendocrine testing. Human CRF
(100 mg) was administered 16 h later at 15:00 hours.
Table 1. Characteristics of study groups
Variable Patients (n=34) Controls (n=25) Test statistic p value
Mean age (years) 42.91 42.72 t=0.97 0.923
Education (mean rank) 29.53 30.64 U=409 0.796
Having child(ren) 25 (74%) 19 (76%) x2=0.046 0.829
Living alone 6 (18%) 6 (24%) x2=0.359 0.549
Employment status : working 1 (2,9%) 25 (100%) x2=55.062 <0.001
Mean body mass index 24.57 24.75 U=398 0.679
Mean time diagnosis (months) 31.91 – – –
Checklist Individual Strength
Fatigue (mean) 46.03 21.28 U=36 <0.001
Concentration (mean) 28.94 11.36 U=29.5 <0.001
Motivation (mean) 15.73 8.64 U=109.5 <0.001
Physical activity (mean) 14.77 5.24 U=59.5 <0.001
Total score (mean) 105.5 46.52 U=14 <0.001
Current psychiatric disorder
Somatization disorder 8 (24%) 0 Fisher’s exact 0.008
PTSD 0 0 – –
Other anxiety disorder 9 (26%) 3 (12%) x2=1.862 0.172
MDD (past) 16 (47%) 7 (28%) x2=2.053 0.152
Early-life stress 12 (35%) 10 (40%) x2=0.136 0.712
Oral estrogen 8 (24%) 2 (8%) Fisher’s exact 0.166
Psychotropic medication
Antidepressant 13 (38%) 0 x2=12.260 <0.001
Benzodiazepine 21 (62%) 2 (8%) x2=17.508 <0.001
PTSD, Post-traumatic stress disorder ; MDD, major depressive disorder.
Signiﬁcant diﬀerences are indicated in bold.
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p=0.005 ; AUCnet, p=0.003). Furthermore, there
were no signiﬁcant diﬀerences in the distributions of
the three Dex/CRF variables when dividing the
patient sample on the basis of benzodiazepine use
(p>0.22, benzodiazepines higher mean rank) or anti-
depressants (p>0.38, antidepressants higher mean
rank, except for Basal).
Patients who took an oral oestrogen (n=8) showed
signiﬁcantly lower cortisol responses in the combined
Dex/CRF test than patients who did not take an oral
oestrogen (n=26), as measured by AUCnet (p=0.023).
The values of AUCtot were also lower in the oestro-
gen group, whereas the values of Basal were higher.
However, the diﬀerences for these two variables were
not statistically signiﬁcant between the two groups
(Mann–Whitney, two-sided: Basal, p=0.350 ; AUCtot,
p=0.417). Since there was a higher frequency of sub-
jects taking an oral oestrogen in the patient group
compared with the control group (see Table 1), oral
oestrogens could have represented a confounding
factor in the previous analyses. Therefore, we per-
formed an additional analysis after removal of the
eight patients and two control subjects taking an oral
oestrogen. Fig. 2 presents the mean free salivary cor-
tisol responses in CFS patients with and without ELS
and controls in the combined Dex/CRF test after
removal of subjects taking an oral oestrogen. The cor-
tisol responses before and after CRF were clearly
lower in patients without ELS than in the other
two groups. Table 3 lists the mean values of the three
Dex/CRF variables with the standard deviations. The
diﬀerences in distributions of Basal and AUCtot were
signiﬁcant in the (one-sided) analysis between two
groups (patients and controls) and in the analysis
between three groups (patients with and without
ELS and controls), but not the diﬀerences in distri-
butions of AUCnet. The Dunn test for post-hoc
analysis revealed signiﬁcant diﬀerences for Basal and
AUCtot between ELSx patients and controls, and be-
tween the ELSx and ELS+ patients. The diﬀerences
between the ELS+ patients and controls were not
signiﬁcant for any of the variables. Comparable results
were obtained when excluding controls with a past
history of ELS: patients (n=26) versus controls ELSx
(n=14) : Mann–Whitney, two-sided: Basal, p=0.050;
AUCtot, p=0.033 ; AUCnet, p=0.427. Patients ELS+
(n=15) versus patients ELSx (n=11) versus controls
ELSx (n=14) : Kruskal–Wallis : Basal, p=0.004;
AUCtot, p=0.008; AUCnet, p=0.223 (Dunn: signiﬁcant
diﬀerences for Basal and AUCtot between ELSx
patients and controls, and between ELSx and ELS+
patients).
Table 2. Mean values of the three computed variables in the combined low-dose
dexamethsone/corticotropin-releasing factor test in patients and controls
Variable Patients Controls U statistic p value
Basal 38.01 (30.11) 76.63 (75.69) 309 0.038
AUCtot 5557.47 (5168.48) 11076.49 (10904.67) 283 0.015
AUCnet 2706.42 (3940.16) 5329.18 (7187.03) 342 0.102
Basal, mean salivary cortisol concentration (ng/100 ml) over three time-points
after dexamethasone but before CRF; AUCtot is the total area under the curve
and represents the total cortisol output after CRF; AUCnet is identical to AUCtot,
except for removal of the area between ground and Basal.
Standard deviations are presented within parentheses. In the non-parametrical
testing (Mann–Whitney, one sided), patients (n=34) showed signiﬁcantly lower
values of Basal and AUCtot and a trend towards lower values of AUCnet compared
to controls (n=25).
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Fig. 2.Mean salivary (free) cortisol values (ng/100 ml)¡S.E.M.
at seven time-points during the combined low-dose
dexamethasone/corticotropin-releasing factor (CRF)
test in CFS patients with (ELS+,2, n=11) and without
(ELSx,&, n=15) early-life stress and control subjects
(m, n=23) after removal of the eight patients and two controls
who were taking an oral oestrogen.
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Discussion
This is the ﬁrst study to investigate HPA axis function
in patients with CFS by means of the combined Dex/
CRF test and also to examine the inﬂuence of a history
of ELS on the outcome in this test. We intentionally
administered a low dose of Dex (0.5 mg) because of
the a priori hypothesis that CFS would be associated
with an enhanced glucocorticoid feedback and/or a
reduced central drive of the HPA axis. In accordance
with this hypothesis, the salivary free cortisol re-
sponses in the combined Dex/CRF test were lower
in CFS patients than in controls.
The total free cortisol responses before (Basal) and
after CRF (AUCtot) were signiﬁcantly diﬀerent be-
tween the two groups. The diﬀerences in absolute
free cortisol output after CRF (AUCnet) did not reach
statistical signiﬁcance, although CFS patients showed
lower values than controls. A larger sample may be
required to examine AUCnet in CFS.
In MDD, the high-dose (1.5 mg) Dex/CRF test has
been shown to be more sensitive than the Dex sup-
pression test (Heuser et al. 1994a). The results of the
current study do not point to the same conclusion
with regard to the low-dose Dex/CRF test in CFS.
More precisely, comparable p values were obtained
for Basal and AUCtot (see Table 3). The less invasive
low-dose Dex suppression test may be sensitive
enough to examine the glucocorticoid feedback func-
tion in CFS, but further studies on the validity of these
tests in CFS are required.
The current ﬁndings are consistent with the ﬁnd-
ings from Gaab et al. (2002b). These authors demon-
strated enhanced suppression of salivary free cortisol
after the administration of a low-dose of Dex (0.5 mg)
in CFS. Recently, Jerjes et al. (2007) reported a higher
level of cortisol suppression after predisnolone in
CFS, providing further evidence for enhanced nega-
tive feedback sensitivity in CFS. Next to the gluco-
corticoid negative feedback mechanism, the outcome
in the combined Dex/CRF test may also inﬂuenced
by the central drive of the HPA axis (Holsboer,
2000). Regarding to this, several studies have pointed
to a reduced hypothalamic central secretion of CRF
and arginine vasopressin or to a reduced supra-
hypothalamic stimulus to the HPA axis in CFS
(Demitrack et al. 1991 ; Scott et al. 1998a, 1999 ; Altemus
et al. 2001; Gaab et al. 2002a), although there have
also been negative reports (Moorkens et al. 2000;
Cleare et al. 2001 ; Inder et al. 2005). Alternatively, de-
sensitization of target receptors on anterior pituitary
corticotropes may also explain the reduced cortisol
output in CFS, although this is inconsistent with
hypothalamic deﬁciency (Scott et al. 1998a, 1999).
Furthermore, other neurobiological pathways may
also be involved primarily or secondarily in HPA axis
dysfunction. For instance, studies measuring cortisol
and prolactin responses to a serotonin agonist have
provided evidence for a disturbed relationship be-
tween the serotonergic system and the HPA axis in
CFS (Parker et al. 2001).
Further analysis revealed an inﬂuence of ELS
and oestrogen intake on the cortisol responses.
Interestingly, patients without a history of ELS
showed signiﬁcantly lower cortisol responses than
patients with ELS and controls. CFS patients with ELS
did not show a signiﬁcantly enhanced glucocorticoid
negative feedback. This is not surprising when con-
sidering the ﬁndings of Rinne et al. (2002), who
demonstrated that ELS was associated with an en-
hanced ACTH and cortisol response in the combined
high-dose Dex/CRF test in women with borderline
Table 3. Mean values of the three computed variables in the combined low-dose dexamethsone/corticotropin-releasing factor test when
diﬀerentiating patients on the basis of early-life stress (ELS) and after removal of eight patients and two control subjects who were taking
an oral oestrogen
Variable Patients total Patients ELSx Patients ELS+ Controls
U statistic
[1]
x2 statistic
[2]
p value
[1]
p value
[2]
Basal 34.91 (27.23) 24.03 (20.59) 49.76 (28.98) 80.86 (77.47) 196 10.730 0.020 0.005
AUCtot 5979.71 (5608.31) 3964.22 (3557.18) 8728.11 (6820.24) 11796.56 (11084.35) 190 9.599 0.015 0.008
AUCnet 3361.19 (4153.22) 2162.17 (2400.53) 4996.22 (5473.42) 5732.07 (7363.95) 252 3.128 0.173 0.209
For an explanation of the variables see Table 2. Standard deviations are presented within parentheses. When repeating the
statistical analyses without the eight patients and two control subjectss who were taking an oral oestrogen, the diﬀerences in
distributions of Basal and AUCtot were signiﬁcant in the (one-sided) analysis between patients (total sample, n=26) and controls
(n=23) [1] and in the analysis between patients without ELS (ELSx) (n=15) and with ELS (ELS+) (n=11) and controls [2],
but not the diﬀerences in distributions of AUCnet. The Dunn test for post-hoc analysis revealed signiﬁcant diﬀerences for Basal
and AUCtot between the ELSx patients and controls and between ELSx and ELS+ patients. The diﬀerences between the ELS+
patients and controls were not signiﬁcant for any of the variables.
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personality disorder, pointing to an enhanced central
CRF drive and/or a reduced glucocorticoid negative
feedback, rather than the opposite. In contrast, there
have also been reports of an enhanced glucocorticoid
negative feedback in patients who experienced ELS
(Stein et al. 1997 ; Newport et al. 2004). However,
in both studies, patients with ELS showed a high
co-morbidity of current PTSD (94% and 68% respect-
ively), a syndrome that has been associated with en-
hanced glucocorticoid negative feedback (Yehuda
et al. 1993). Moreover, in the previously mentioned
study by Rinne et al. (2002), co-morbid PTSD was
shown to attenuate the ACTH response in the com-
bined Dex/CRF test. Furthermore, in the studies by
Newport et al. (2004) and Yehuda et al. (2004), ELS was
only associated with Dex hypersuppression in patients
with co-morbid MDD or PTSD, respectively. This
suggests that enhanced glucocorticoid feedback is not
an invariable consequence of ELS, but is more related
to the resultant psychiatric illness in traumatized
individuals. In the current study, PTSD or MDD were
not confounding factors, since none of the participants
were diagnosed with current PTSD or MDD. Further
research on the neuroendocrine characteristics of ELS
is required.
Some limitations need to be considered when
interpreting the results. All patients were female
and they were all attending a tertiary care centre.
Consequently, we cannot directly extrapolate these
results to male CFS patients and to CFS patients in
primary or secondary care. The validity of retrospec-
tive reports of ELS has been critically discussed
(Widom et al. 2004). Problems include : accuracy, recall
bias, sampling bias and examination of causal re-
lationships. However, the conclusion of a review on
this topic was that retrospective reports of ELS are
suﬃciently valid, if they rely on reasonable oper-
ationalization (Hardt & Rutter, 2004). Although there
are no clear-cut guidelines for severity rating of child
abuse, we focused on behaviors that unambiguously
point to physical or sexual abuse. When applying
the operational criteria, ELS could clearly be rated for
each subject. Furthermore, the frequency of abuse has
previously been found to be a reliable predictor of
neuroendocrine sequels of ELS (Rinne et al. 2000,
2002). According to Hardt & Rutter (2004), retrospec-
tive reports are likely to provide underestimates of
the incidence of abuse or neglect, rather than over-
estimates. Regarding this, the use of a structured
interview is likely to be more valid than a question-
naire. The rates for ELS in the control subjects (40%)
were slightly higher than the ones reported in a large
study with 8667 participants (35%) (McCauley et al.
1997). However, the high prevalence of ELS did
not aﬀect the results of this study. More precisely,
comparable results were obtained after excluding
controls with a history of ELS. In contrast with the
studies by Van Houdenhove et al. (2001) and Heim
et al. (2006), there was no higher rate of ELS in CFS.
This may be due to the fact that in the current study,
emotional neglect and adult victimization were not
assessed.
Furthermore, concentrations of ACTH were not
measured in the combined Dex/CRF test. Therefore,
it cannot be excluded that the observed lower
cortisol output in CFS patients is due to adrenal in-
suﬃciency. However, in two challenge studies with
o1 mg ACTH, there were no diﬀerences in cortisol re-
sponses between CFS patients and healthy subjects
(Hudson & Cleare, 1999 ; Gaab et al. 2003b), suggest-
ing that adrenal insuﬃciency is unlikely to play a
signiﬁcant role in CFS. Scott et al. (1998c) and
Demitrack et al. (1991) reported reduced cortisol re-
sponses in the ACTH test, but taking the ﬁndings of
challenge studies into account, both research groups
interpreted these results as a diminished adreno-
cortical reserve in CFS, secondary to a reduced
stimulation from pituitary ACTH. Another limitation
is the absence of a baseline collection of salivary cor-
tisol at the same time of day without Dex. Therefore,
it cannot be excluded that patients were hypocorti-
solaemic at baseline, with a subsequent reduced re-
sponse to both Dex and CRF. However, in every
analysis, the values of the absolute cortisol increase
after CRF (AUCnet) were lower in CFS patients com-
pared to controls (see Tables 2 and 3). Based on this
ﬁnding and on the results of the previously mentioned
study by Gaab et al. (2002b) (in which there was no
signiﬁcant baseline diﬀerence between patients and
controls), it seems unlikely that the diﬀerences in
total free salivary cortisol concentrations between CFS
patients and controls after Dex and after CRF were
only due to a possible baseline hypocortisolism in
CFS. An additional limitation is that it cannot be ex-
cluded that there was no suppression in the control
group, resulting in a CRF test in this group, rather
than a Dex/CRF test. However, the values of
salivary cortisol after 0.5 Dex (CFS patients : 38.01 ng/
100 ml=1.05 nmol/l ; controls : 76.63 ng/100 ml=
2.11 nmol/l ; see Table 2) were very low in both
groups, pointing to Dex suppression. Moreover,
these salivary cortisol values were comparable with
the values at the 15 :00 hours time-point after 0.5 mg
Dex in the study by Gaab et al. (2002b). These authors
did measure baseline salivary cortisol and reported
signiﬁcantly lower values after 0.5 mg Dex in both CFS
patients and controls (although a stronger decrease
in CFS patients). Taking this evidence into account,
it is unlikely that there was no suppression in the
control group in our study.
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Psychotropic drugs may have an inﬂuence on HPA
axis function, but there was no signiﬁcant inﬂuence
of antidepressants or benzodiazepines in this study
(and the CRF response was even higher in patients
taking those medications). In accordance with the
ﬁndings of Kirschbaum et al. (1999), oestrogen intake
aﬀected the absolute free cortisol concentrations after
CRF (AUCnet). Oestrogens induce an increased pro-
duction of corticosteroid-binding globulin, resulting
in a reduced fraction of free cortisol (Kirschbaum
et al. 1999). The frequency of oestrogen intake was
higher in the patient group, but the main ﬁndings of
this study remained signiﬁcant after correcting for
this confounding factor (Table 3). However, we did
not control for menstrual cycle or menopause status,
nor did we control for Dex plasma levels.
In conclusion, CFS was associated with reduced
cortisol responses in the combined low-dose Dex/CRF
test, but this eﬀect was only signiﬁcant in CFS patients
without a history of ELS. This study provides further
support for an enhanced glucocorticoid negative feed-
back and/or a reduced central HPA axis drive in CFS.
Further validation of the low-dose Dex suppression
test and Dex/CRF test in CFS is required. Further-
more, CFS with and without a history of ELS are
possibly diﬀerent from a neurobiological point of view,
and future studies on the pathogenesis and treatment
of the disorder should take this into account.
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